6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

15 trials found

diseases per page:

Showing 1 to 10 of 15 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-004344-19-DE (EUCTR)	07/02/2017	27/09/2016	An international trial of deferiprone in patients with Parkinson’s disease	A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of DeferiproneDelayed Release Tab ...	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Product Name: Deferiprone 600 mg delayed release tablet INN or Proposed INN: DEFERIPRONE	ApoPharma	NULL	Not Recruiting			Female: yes Male: yes	140	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France;Canada;Germany;United Kingdom
2	NCT02728843 (ClinicalTrials.gov)	October 12, 2016	31/3/2016	Study of Parkinson's Early Stage With Deferiprone	A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of DeferiproneDelayed Release Tab ...	Parkinson's Disease	Drug: Deferiprone;Drug: Placebo	ApoPharma	NULL	Completed	18 Years	80 Years	All	140	Phase 2	Canada;France;Germany;United Kingdom
3	EUCTR2015-003679-31-NL (EUCTR)	09/08/2016	24/05/2016	New therapeutic strategy in Parkinson’s disease	Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II	De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE	Centre Hospitalier Régional et Universitaire de Lille	NULL	Not Recruiting			Female: yes Male: yes	338	Phase 2	Portugal;Czech Republic;Spain;Austria;Netherlands
4	EUCTR2015-004344-19-FR (EUCTR)	29/06/2016	20/04/2016	An international trial of deferiprone in patients with parkinson’s disease	A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of DeferiproneDelayed Release Tab ...	Parkinson’s disease MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Product Name: Deferiprone 600 mg delayed release tablet INN or Proposed INN: DEFERIPRONE	ApoPharma Inc.	NULL	Not Recruiting			Female: yes Male: yes	140	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;France;Canada;Germany;Italy;United Kingdom
5	EUCTR2015-003679-31-CZ (EUCTR)	23/06/2016	28/01/2016	New therapeutic strategy in Parkinson’s disease	Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II	De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE	Centre Hospitalier Régional et Universitaire de Lille	NULL	Not Recruiting			Female: yes Male: yes	338	Phase 2	Portugal;Czech Republic;Spain;Austria;Netherlands
6	EUCTR2015-003679-31-PT (EUCTR)	18/04/2016	28/01/2016	New therapeutic strategy in Parkinson’s disease	Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II	De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE	Centre Hospitalier Régional et Universitaire de Lille	NULL	Not Recruiting			Female: yes Male: yes	338	Phase 2	Portugal;Czech Republic;Spain;Austria;Netherlands
7	EUCTR2015-003679-31-AT (EUCTR)	06/04/2016	11/01/2016	New therapeutic strategy in Parkinson’s disease	Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease - FAIRPARK II	De Novo Parkinson’s disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE	Centre Hospitalier Régional et Universitaire de Lille	NULL	Not Recruiting			Female: yes Male: yes	372	Phase 2	Portugal;France;Czech Republic;Spain;Austria;Netherlands;Germany;United Kingdom
8	EUCTR2015-004344-19-GB (EUCTR)	31/03/2016	16/02/2016	An international trial of deferiprone in patients with Parkinson’s disease	A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of DeferiproneDelayed Release Tab ...	Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Product Name: Deferiprone 600 mg delayed release tablet INN or Proposed INN: DEFERIPRONE	ApoPharma	NULL	Not Recruiting			Female: yes Male: yes	140	Phase 2	France;Canada;Germany;United Kingdom
9	EUCTR2015-003679-31-ES (EUCTR)	21/03/2016	13/01/2016	New therapeutic strategy in Parkinson?s disease	Conservative iron chelation as a disease-modifying strategy in Parkinson?s disease: a multicentre, p ...	De Novo Parkinson?s disease MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkin ...	Trade Name: Ferriprox 500 mg Product Name: Deferiprone DR INN or Proposed INN: DEFERIPRONE	Centre Hospitalier Régional et Universitaire de Lille	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	338	Phase 3	Spain
10	NCT02655315 (ClinicalTrials.gov)	February 9, 2016	7/1/2016	Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease	Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multice ...	Parkinson Disease	Drug: Deferiprone;Drug: Placebo	University Hospital, Lille	European Commission;ApoPharma	Completed	N/A	80 Years	All	372	Phase 2	Austria;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;Czech Republic

First Previous1 2Next Last